SymptomManagement and Supportive Care Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety

Disclosures of potential conflicts of interest may be found at the end of this article. Key Words. Aprepitant x Chemotherapy-induced nausea and vomiting x Fosaprepitant x Highly emetogenic chemotherapy x Moderately emetogenic chemotherapy x Neurokinin-1 receptor antagonist Chemotherapy-induced nausea and vomiting (CINV) is a com-mon adverse event associated with anticancer treatment that canhavea significantadverse impactonpatienthealth-related quality of life and that can potentially undermine the effec-tiveness of chemotherapy. Traditional regimens to prevent CINV generally involved a combination of a corticosteroid plus a 5-hydroxytryptamine (5HT3) receptor antagonist (RA). In the past 10 years, antiemetic treatment has greatly advancedwith the availability of the neurokinin-1 receptor antagonist (NK1 RA) aprepitant and its prodrug fosaprepitant. NK1 RAs have a different mechanism of action in CINV than corticosteroid